PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised

Key Takeaways Puma Biotechnology posted Q3 adjusted EPS of $0.21, which topped estimates but fell from last year's $0.45.Q3 revenues of $54.5 million beat expectations but declined 32.3% year over year on weaker royalty income.PBYI raised 2025 revenue guidance to $220-$223 million, while increasing Nerlynx product sales outlook.Puma Biotechnology (PBYI) reported third-quarter 2025 adjusted earnings of 21 cents per share, which beat the Zacks Consensus Estimate of 9 cents. In the year-ago quarter, the compan ...